We will pursue safety and trust in pharmaceutical products, helping to contribute to enhancing corporate value
Masanobu Kono
Executive Officer, Head of Quality & Vigilance Div.
The mission of the Quality & Vigilance Division is to provide the universal values of safety and trust demanded in the pharmaceutical sector. In this division, we work to maintain and improve safety and trust in our products and business activities while linking the two axes of quality and safety.
Specifically, maintaining stable supply while responding to the increasingly stringent regulations and rising expectations for pharmaceutical quality has become a major challenge. We will strengthen management at manufacturing facilities in Japan and overseas, improve quality control systems on an ongoing basis, and provide a stable supply of pharmaceuticals, and in doing so, build good relations with all of our stakeholders. Pharmaceutical products are only safe and effective when used appropriately. To that end, we will work to minimize the risks inherent in pharmaceutical products and to communicate information on these risks by summarizing specialist information so that it is easy to understand. In addition, we will enhance the training and education provided to our employees, offering safety and trust by fulfilling our responsibility to be accountable to all of our stakeholders.
Currently, our priority is to enhance the quality of our safety management and quality assurance. To achieve that, we are focusing on the following four points. First, preventative and proactive quality assurance. Rather than responding after a problem has occurred, we will construct systems to predict, evaluate, and prevent risks. Second, use of digital technology. We are deploying advanced technologies such as RPA and AI, improving the accuracy and effectiveness of our quality assurance and safety management operations. Third, compliance with global standards. We are strengthening cooperation with overseas locations to allow us to deal flexibly with the regulations of different countries and the needs and cultures of the countries in which we sell our products. Fourth and last, improvement of our organization and our human resources. To improve the technical skills, ethics, leadership, and strategic thinking of human resources in the quality assurance and safety management divisions, we are promoting the introduction of a quality-focused culture and the adoption of continuing education programs. Through these initiatives, we will improve the quality of our safety management and quality assurance and work to further strengthen the trust placed in us by patients and healthcare professionals.
Our goal for the future is to increase corporate and enterprise value. By communicating valuable safety information that reflects the needs of the medical community and ensuring the stable supply and quality of pharmaceutical products, we will maintain and build on the trust we receive from patients, the medical field, and society as a whole, which will increase corporate and enterprise value.
Furthermore, for a pharmaceutical business, a robust research and development pipeline leads directly to increased corporate and enterprise value. To increase the success rate of our development efforts and provide choices that offer hope to those who are facing an illness, management decisions must be reliable and swift, based on trustworthy data to advance development to the next stage. Treating the transition to a new management system as an opportunity, we will further accelerate efforts made to date, avoiding risk from the perspective of quality and safety. We will change the lives of our patients, offering pharmaceutical products that inspire happiness, and work to become an enterprise with a global presence.